Overview

A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole

Status:
Completed
Trial end date:
2021-03-08
Target enrollment:
Participant gender:
Summary
A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214-02 to Rabeprazole in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Addpharma Inc.
Treatments:
Rabeprazole